Our Story
Lucy Biotech provides cutting-edge technologies for cryopreserving cells, tissues, and organs. Our solutions are inspired by nature and it is effective and non-toxic. Founded by a group of Canadian scientists who were fascinated by arctic species, today we offer an innovative approach to combat current challenges in cryobiology worldwide. Get in touch today to learn more.
Meet the Management Team
Igniting Hong Kong's Biotech Renaissance with Advanced Cryopreservation
President
Ken Lee
Ken Lee is the founder of Lucy Biotech and holds an MBA from the Richard Ivey School of Business. Ken has over 25 years of biotech industry experience, and is very seasoned in preclinical and clinical development of biologics. As President & CEO at iProgen Biotech, Ken managed all aspects of the business operations, including financing, implementation of business plans, communication towards stakeholders, recruiting and managing employees, and developing collaborations and partnerships.
Senior Advisor
Vivien Webb
Vivien experienced more than 35 years in private wealth management in Asian, working across several top international institutions, including Morgan Stanley, Goldman Sachs, HSBC, and Chase Manhattan Bank. Throughout her career, Vivien enjoyed senior-level relationship management and advisory responsibilities, witnessing a tremendous increase in Asian-based entrepreneurs who not only built fast-growing successful businesses but also sought to use their success philanthropically.
Chief Executive Officer
Melodie Lu
Melodie Lu has been the CEO and a member of the Board of Directors for Lucy Biotech since November 2022. Prior to becoming a member of Lucy, Melodie amassed 7 years as the director of operations at iProgen Biotech Inc. Melodie began her career at the Jack Bell Research Centre at the University of British Columbia then, transitioned to work in a start-up biotech company. She leads a team of scientists and technicians in recombinant protein production.
Senior Advisor
Virginia Devereux Wong
Virginia’s career spans over 35 years in the mutual fund industry with a strong track record of business success and a renowned reputation in establishing new businesses. Virginia first became involved in the funds industry in 1987 and has since established her asset management business in private partnership, and subsequently, in working for global asset managers and major investment banks, such as SEI, Goldman Sachs, Standard Life Investments and HSBC Global Private Banking. She currently serves as a Senior Advisor and Board Member for AutoML Capital, an AI Powered Investment Management Company. She also serves as a Board member of Pathfinders Hong Kong (Non-Profit).
VP of Business Development
Nigel McNabb
Nigel McNabb has close to 20 years of experience in corporate and business development. As a seasoned business development expert, Nigel has worked as a Business Transformation Consultant, Business Architect, as well as a Project Manager. His key areas of expertise include innovative business strategy, design and implementation. Nigel holds a B.Sc. in Biology from the University of British Columbia and an MBA from the Richard Ivey School of Business.
Meet the Scientists
Chief Scientific Officer
Dr. Leo Lin
Dr. Lin is the Chief Scientific Officer at Lucy Biotech. He received the Governor’s Gold Medal for best thesis in Ph.D. of Biochemistry from McGill University in Canada. He then proceeded to complete his post-doctoral fellowship at the University of British Columbia. Now, he leads the research and development team of Lucy. He also is the co-inventor of all iProgen patents.
Research Associate
Dr. Sinai H. Cortes
Dr. Cortes has always been passionate about improving human health. After years of dentistry practice as a trained dental surgeon, Dr. Cortes started her journey in biomedical research in 2016. She studied regenerative medicine with projects specific to bone regeneration and obtained her master’s degree in oral biology at the Universidad Nacional Autonoma de Mexico (UNAM). She continued her research in tissue engineering and heart regeneration through cryo-injury while completing her PhD at the City University of Hong Kong. Her findings showed that low-temperature procedures can potentially induce the healing of infarcted hearts. Her work extends the knowledge of molecular mechanisms involved in the novel cell death signalling pathways and tissue regrowth at extremely low temperatures. Dr. Cortes joins Lucy Biotech to continue her work of utilizing cryobiology in translational medicine.
Scientific Advisor
Dr. Caigan Du
Dr. Du has amassed more than 20 years of field work in Biochemistry, mainly specifying in kidney donor-derived factors. These include renal allograft rejection, the molecular pathways of kidney injury, and regeneration. He received his Ph.D. from the University of Wales in the United Kingdom, as well as completing two post-doctoral training in Molecular Genetics and Immunology at the University of Tennessee and Vanderbilt University in the United States. Dr. Du continues to lead research as a Director in developing genius preservation methods for donor organs at the Guoke Ningbo Life and Sciences Research Centre.
Research Technician
Victoria Seo
Victoria joined Lucy Biotech as a Research Technician. She obtained her Bachelor of Biomedical Sciences degree from the University of Hong Kong. Prior to joining Lucy biotech, she worked in Bayer Korea as a medical intern in the field of cardiovascular health. Driven by her research interests in regeneration medicine, she aspires to contribute to Lucy Biotech's mission in cryobiology and its application in translational medicine.